Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad, +17

The Lancet Oncology

Advanced Met-positive GastricFirst-line TherapyGastrointestinal OncologyMedicineMetronomic Therapy +5

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin, +12

The Lancet Oncology

Gastrointestinal OncologyMedicinePathologyFirst-line TreatmentPharmacotherapy +6

A single-cell transcriptomic landscape of the lungs of patients with COVID-19

Si Wang, Xiaohong Yao, Shuai Ma, +40

Nature Cell Biology

Lung InflammationMedicineSingle Cell SequencingImmunologyVirology +4

Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system

Rui Tang, Limin Li, Dihan Zhu, +7

Cell Research

ChromatinEngineeringMedicineGeneticsRna Biology +10

A cohort autopsy study defines COVID-19 systemic pathogenesis

Xiao-Hong Yao, Tao Luo, Yu Shi, +33

Cell Research

Geo-economic variations in epidemiology, patterns of care, and outcomes in patients with acute respiratory distress syndrome: insights from the LUNG SAFE prospective cohort study

John G. Laffey, Fabiana Madotto, Giacomo Bellani, +894

The Lancet Respiratory Medicine

Acute Lung InjuryPulmonary CareHealth EconomicsRespiratory Distress Syndrome (Pulmonary Critical Care)Acute Care +9

Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer

Huan Zeng, Yixuan Hou, Xinyue Zhou, +11

Theranostics

Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.

Eunice L. Kwak, Patricia LoRusso, Omid Hamid, +10

Journal of Clinical Oncology

Esophageal CancerCancer ManagementGastroenterologyPathologyTumor Biology +15

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer

Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, +15

Clinical Cancer Research

An LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation

Christopher W. Murray, Jennifer J. Brady, Min K. Tsai, +8

Cancer Discovery